The results between CDH11 and the clinical features of GC patients showed that CDH11 overexpression is distinctly associated with worse pathological features such as EMT, metastatic status, higher T stage, and tumor mutation burden (TMB). This evidence concerns the gene CDH11 and gastric cancer.